Eli Lilly & Company (Lilly) is a global pharmaceutical company, developing therapies for various diseases.
Lilly was first company to mass-produce penicillin and was also, one of the first to produce human insulin using rDNA technology. Also, Presently Lilly is the world’s largest manufacturer and distributor of psychiatric medications.
In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer.
- In May 2020, the US FDA granted accelerated approval to RETEVMO (selpercatinib/LY3527723) RET inhibitor for the following indications : Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy and Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- In Sep 2017, Verzenio™ (abemaciclib) was US FDA approved in combination with fulvestrant for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer with disease progression following endocrine therapy, and as monotherapy for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
- In Apr 2015, FDA approved Ramucirumab for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first line bevacizumab-, oxaliplatin- and fluoropyrimidine-containing regimen.
- In Dec 2014, US FDA approved Ramucirumab in combination with docetaxel, for treatment of metastatic non-small-cell lung carcinoma with disease progression on or after platinum-containing chemotherapy.
- In Apr 2014, FDA approved Ramucirumab (CYRAMZA), as a single agent or with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma if the disease has progressed despite platinum-containing chemotherapy.
- In 2004, Alimta®/Pemetrexed was FDA approved for the treatment of malignant pleural mesothelioma & for NSCLC in 2009.
- In 1996, Eli Lilly’s Gemzar®/Gemcitabine was approved by FDA as first line treatment for pancreatic cancer and was later approved for NSCLC, Breast cancer and Ovarian Cancer as first line treatment in combination of different chemotherapy.
Page 1 of 2
